Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hindustan Bio Sciences (BOM:532041) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hindustan Bio Sciences EBITDA Margin % Related Terms
Hindustan Bio Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hindustan Bio Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hindustan Bio Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hindustan Bio Sciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hindustan Bio Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hindustan Bio Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hindustan Bio Sciences (BOM:532041) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hindustan Bio Sciences and its competitors. According to the industry distribution chart, Hindustan Bio Sciences ranks #769 out of 961 companies in the Drug Manufacturers industry, placing it in the top 80%.
Is Hindustan Bio Sciences' EBITDA Margin % too high?
Hindustan Bio Sciences' current EBITDA Margin % is 0.00%. Based on the distribution chart, Hindustan Bio Sciences ranks #769 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hindustan Bio Sciences has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hindustan Bio Sciences' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hindustan Bio Sciences ranks #769 out of 961 companies for EBITDA Margin %. This places Hindustan Bio Sciences in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hindustan Bio Sciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hindustan Bio Sciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hindustan Bio Sciences stock overvalued right now?
Based on GuruFocus' analysis, Hindustan Bio Sciences (BOM:532041) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6.11, compared to a current price of ₹7.20 — trading 17.8% above its estimated fair value. The current EBITDA Margin % is 0.00%. Hindustan Bio Sciences' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hindustan Bio Sciences (BOM:532041), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hindustan Bio Sciences (BOM:532041) Overvalued in 2026?
Based on GuruFocus' analysis, Hindustan Bio Sciences stock appears to be overvalued.
The current stock price of ₹7.20 is trading 17.8% above its estimated GF Value™ of ₹6.11.
GuruFocus considers Hindustan Bio Sciences to be Modestly Overvalued.
Key valuation signals for BOM:532041:
EBITDA Margin %: 0.00%
GF Value™: ₹6.11 vs. price of ₹7.20 (17.8% above fair value)
No single metric tells the full story. See the BOM:532041 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hindustan Bio Sciences Ltd is an Indian pharmaceutical company, engaged in the manufacturing and sale of pharmaceutical products. The company manufactures and markets drugs and medicines in tablets, capsules, drops, externels, and syrup forms. Geographically, all of its revenue is generated through the export of its products to international markets.
51GF Score
Get the complete analysis for BOM:532041
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532041 has been successfully added to your 
